Compare USEG & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | USEG | VERU |
|---|---|---|
| Founded | 1966 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.5M | 41.7M |
| IPO Year | 1995 | 1996 |
| Metric | USEG | VERU |
|---|---|---|
| Price | $1.15 | $2.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $3.50 | ★ $22.50 |
| AVG Volume (30 Days) | ★ 4.9M | 65.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $32,379,000.00 | $16,296,958.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $57.52 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.91 | $0.36 |
| 52 Week High | $2.75 | $4.59 |
| Indicator | USEG | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 54.26 | 57.83 |
| Support Level | $1.12 | $2.15 |
| Resistance Level | $1.29 | $2.77 |
| Average True Range (ATR) | 0.11 | 0.16 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 34.21 | 91.67 |
US Energy Corp is an independent energy company. It is focused on the acquisition and development of oil and natural gas-producing properties in the continental United States. It has business properties and operations in the Rockies region (Montana, Wyoming, and North Dakota), the Mid-Continent (Oklahoma, Kansas, and North and East Texas), and the West Texas, South Texas, and Gulf Coast regions. The company generates revenue from its interest in the sales of oil and natural gas production. The group operates in the exploration and production segment of the oil and gas industry, onshore in the United States.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.